JZYY(600750)2025-01-24 09:30Financial Performance - In 2024, the company achieved total operating revenue of 443.545 million yuan, a decrease of 2.59% compared to the previous year[3] - The net profit attributable to shareholders was 78.491 million yuan, an increase of 9.22% year-on-year[3] - The basic earnings per share rose to 1.25 yuan, reflecting a growth of 9.65% from the previous year[3] - The weighted average return on equity increased to 19.90%, up by 1.92 percentage points compared to the previous year[3] - Total assets at the end of the reporting period were 648.914 million yuan, an increase of 1.37% from the beginning of the period[3] - The equity attributable to shareholders decreased by 1.36% to 386.059 million yuan[3] - The financial data presented is preliminary and unaudited, with potential discrepancies in the final report[6] Strategic Focus - The company is focusing on strengthening its OTC products, developing health products, and expanding its prescription drug business as part of its strategic plan[5] - The company is addressing bottlenecks to high-quality development by accelerating its focus on core business, technological innovation, and organizational transformation[5] Business Acquisition - The company acquired 51% equity in Jiangxi Jiangzhong Traditional Chinese Medicine Co., Ltd. from its controlling shareholder, which constitutes a business combination under common control[4]